CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

Search

Pitney Bowes Inc

Gesloten

SectorIndustrieën

10.57 3.53

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.21

Max

10.76

Belangrijke statistieken

By Trading Economics

Inkomsten

-25M

27M

Verkoop

18M

478M

K/W

Sectorgemiddelde

12.345

61.065

EPS

0.45

Dividendrendement

2.9

Winstmarge

5.724

Werknemers

6,600

EBITDA

-30M

92M

Aanbevelingen

By TipRanks

Aanbevelingen

Sell

12 Maanden Prognose

-6.77% downside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.90%

2.23%

Volgende Winsten

6 mei 2026

Volgende dividenddatum

30 mrt 2026

Volgende Ex Dividend datum

18 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-96M

1.7B

Vorige openingsprijs

7.04

Vorige sluitingsprijs

10.57

Nieuwssentiment

By Acuity

29%

71%

97 / 406 Rangschikking in Industrials

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Pitney Bowes Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Pitney Bowes Inc Prognose

Koersdoel

By TipRanks

-6.77% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.5 USD  -6.77%

Hoogste 9.5 USD

Laagste 9.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pitney Bowes Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Sell

2 ratings

0

Buy

1

Hold

1

Sell

Technische score

By Trading Central

9.04 / N/ASteun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

97 / 406 Rangschikking in Industrieën

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pitney Bowes Inc

Pitney Bowes Inc., operates as a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to small businesses, large enterprises, and government entities around the world. It operates through Global Ecommerce, Presort Services, and SendTech Solutions segments. The Global Ecommerce segment provides domestic parcel services, cross-border solutions, and digital delivery services. The Presort Services segment offers mail sortation services, which allow clients to qualify volumes of first-class mail, marketing mail, marketing mail flats, and bound printed matter for postal work sharing discounts. The SendTech Solutions segment provides physical and digital mailing and shipping technology solutions, and other applications for sending, tracking and receiving of letters, parcels, and flats as well as financing alternatives to finance equipment and product purchases. It markets its products, solutions, and services through direct and inside sales force, global and regional partner channels, direct mailings, and digital channels. The company was formerly known as Pitney Bowes Postage Meter Company. Pitney Bowes Inc. was incorporated in 1920 and is headquartered in Stamford, Connecticut
help-icon Live chat